PCP germ genetics study
Part of Infections, Lungs & breathing clinical trials.
This trial is studying the genetic type of the germ that causes Pneumocystis pneumonia (PCP) in people who have had a positive respiratory test. The goal is to better understand the infection, which may help improve treatment in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with Pneumocystis pneumonia (PCP) and had a respiratory test that found a high level of the infection (more than 50 copies per 10 microliters of sample).
- You have not opted out of having your medical data used for research (the UK National Opt-Out).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether low-dose trimethoprim-sulfamethoxazole (also called TMP-SMX) can treat Pneumocystis pneumonia (PCP) in people with weakened immune systems. It may help improve treatment while reducing side effects compared with standard dosing.
This trial tests a new way to diagnose pneumocystis, a lung infection that can affect people with weakened immune systems. It may help find the infection faster and more accurately using samples taken from your lungs.
This trial tests different antibiotics for people with pneumocystis pneumonia who cannot take the standard treatment. It aims to find the best alternative therapy.
This study tests whether treating a specific germ (Pneumocystis jirovecii) in the lungs can reduce the number of COPD flare-ups. If you have COPD with frequent flare-ups and this germ is found in your sputum, you may benefit.
This study looks at how the airways in people with primary ciliary dyskinesia (PCD) react to certain triggers. It aims to understand if these airways are more sensitive, which could help improve treatment for breathing problems.
This study tests a new pneumococcal vaccine (PCV15) to see how well it protects against carrying the bacteria that can cause pneumonia. Healthy adults aged 18–50 who have not had a pneumococcal vaccine in the last 5 years may join.
Hear when a new Pneumocystis Pneumonia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.